Treatment outcomes for multidrug- and rifampicin-resistant tuberculosis in Central and West Africa: a systematic review and meta-analysis

•Multidrug-resistant/rifampicin-resistant tuberculosis remains a major threat to global health, mainly in low-income settings.•We found a successful treatment outcome of 74.6% in Central and West Africa.•The World Health Organization reported an average global success rate of 59% in 2018.•Shorter an...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:International journal of infectious diseases Ročník 124; s. S107 - S116
Hlavní autori: Toft, Asbjørn Langeland, Dahl, Victor Næstholt, Sifna, Armando, Ige, Olusoji Mayowa, Schwoebel, Valérie, Souleymane, Mahamadou Bassirou, Piubello, Alberto, Wejse, Christian
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Canada Elsevier Ltd 01.11.2022
Elsevier
Predmet:
Africa
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Directly Observed Therapy
Drug-resistance
Epidemiology
Humans
Mycobacterium tuberculosis
Rifampin - pharmacology
Rifampin - therapeutic use
Treatment Outcome
Tuberculosis
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Multidrug-Resistant - epidemiology
Treatment outcome
Tuberculosis
Drug-resistance
Epidemiology
Africa
ISSN:1201-9712, 1878-3511, 1878-3511
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:•Multidrug-resistant/rifampicin-resistant tuberculosis remains a major threat to global health, mainly in low-income settings.•We found a successful treatment outcome of 74.6% in Central and West Africa.•The World Health Organization reported an average global success rate of 59% in 2018.•Shorter and standardized regimens may have contributed to better success rates.•Treatment outcome data of multidrug-resistant/rifampicin-resistant tuberculosis is sparse in this region and further investigation is warranted. We aimed to investigate published data on treatment outcomes of multidrug-resistant (MDR)/rifampicin-resistant tuberculosis (TB) in Central and West Africa because these, to the best of our knowledge, are sparsely available. Systematic review and meta-analysis. A total of 14 studies were included, representing 4268 individuals in 14 of the 26 countries. Using a random-effects model meta-analysis, we observed a pooled success rate of 80.8% (95% confidence interval [CI] 56.0-93.3) for the Central African subgroup and 69.2% (95% CI 56.3-79.7) for the West African subgroup (P = 0.0522). The overall treatment success for all studies was 74.6% (95% CI 65.0-82.2). We found high heterogeneity among included studies (I2 = 96.1%). The estimated proportion of successfully treated individuals with MDR/rifampicin-resistant TB was considerably higher than the global estimate provided by the World Health Organization (59%), reaching the 2015 World Health Organization target of at least 75% treatment success for MDR-TB. The use of shorter treatment regimens and the standardized treatment conditions, including directly observed therapy in these studies, could have contributed to a high treatment success. Yet, the available literature was not fully representative of the regions, possibly highlighting the sparse resources in many of these countries. The review was registered at PROSPERO (https://www.crd.york.ac.uk/prospero/) (CRD42022353163).
Bibliografia:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-4
content type line 23
ObjectType-Undefined-3
ISSN:1201-9712
1878-3511
1878-3511
DOI:10.1016/j.ijid.2022.08.015